Thus, inhibition of PD-1/PD-L1 signaling with anti-PD1/PD-L1 agents in order to inhibit immunosuppressive response of tumor cells represents a promising approach in the treatment of HNSCC patients [65]. Here, CD274 is linked to head and neck squamous cell carcinoma.